Evidence map›Paper›PMID 38078321›Full record

ArticleFrontiers in pediatrics2023

Short-, mid-, and long-term complications after multisystem inflammatory syndrome in children over a 24-month follow-up period in a hospital in Lima-Peru, 2020-2022.

Giancarlo Alvarado-Gamarra, Matilde Estupiñan-Vigil, Raquel Garcés-Ghilardi, Jesús Domínguez-Rojas, Olguita Del Águila, Katherine Alcalá-Marcos, Rafael Márquez Llanos, Lucie Ecker, Carlos R Celis, Carlos Alva-Diaz and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Post-MIS-C cardiovascular outcomes: a systematic review.European journal of pediatrics · 2026
    Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Giancarlo Alvarado-GamarraDepartment of Pediatrics, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.
Matilde Estupiñan-VigilDepartment of Pediatrics, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.
Raquel Garcés-GhilardiDepartment of Pediatrics, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.
Jesús Domínguez-RojasDepartment of Pediatrics, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.
Olguita Del ÁguilaDepartment of Pediatrics, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru.
Katherine Alcalá-MarcosInstituto Nacional Cardiovascular "Carlos Alberto Peschiera Carrillo"-INCOR, Lima, Peru.
Rafael Márquez LlanosInstituto Nacional Cardiovascular "Carlos Alberto Peschiera Carrillo"-INCOR, Lima, Peru.
Lucie EckerInstituto de Investigación Nutricional, Lima, Peru.
Carlos R CelisInstituto de Investigación Nutricional, Lima, Peru.
Carlos Alva-DiazGrupo de Investigación Neurociencia, Efectividad Clínica y Salud Pública, Universidad Científica del Sur, Lima, Perú.
Claudio F LanataInstituto de Investigación Nutricional, Lima, Peru.
Hospital Nacional Cayetano Heredia · PEInstituto de Investigación Nutricional · PEDaniel Alcides Carrión National University · PE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To determine the short-, mid-, and long-term complications after multisystem inflammatory syndrome in children (MIS-C) over a 24-month follow-up period in a hospital in Lima, Peru, 2020-2022, and to explore differences according to the immunomodulatory treatment received and type of SARS-CoV-2 virus circulating. Methods: Ambispective 24-month follow-up study in children <14 years of age diagnosed with MIS-C at the Hospital Nacional Edgardo Rebagliati Martins (HNERM). Results: A total of 62 children were admitted with MIS-C. The most common short-term complications and serious events were intensive care unit (ICU) admission, invasive mechanical ventilation (IMV) due to respiratory failure, and shock; predominantly during the second pandemic wave (lambda predominance) and in children that received intravenous immunoglobulin (IVIG) plus a corticosteroid. Two patients died during the first wave due to MIS-C. During prospective follow-up (median of 24 months; IQR: 16.7-24), only 46.7% of patients were followed for >18-24 months. Of the total, seven (11.3%) patients were identified with some sequelae on discharge. Among the 43 remaining children, sequelae persisted in five (11.6%) cases (neurological, hematological, and skin problems). Six patients (13.9%) presented with new onset disease (hematologic, respiratory, neurological, and psychiatric disorders). One patient died due to acute leukemia during the follow-up period. None of them were admitted to the ICU or presented with MIS-C reactivation. Two patients presented persistence of coronary aneurysm until 8- and 24-month post-discharge. Conclusion: In our hospital, children with MIS-C frequently developed short-term complications and serious events during the acute phase, with less frequent complications in the mid- and long-term. More studies are required to confirm these findings.

Indexed as

COVID-19deathhospitalizationlong-term effectmultisystem inflammatory syndrome in childrenpediatric multisystem inflammatory diseasePeru

Identifiers

PMID38078321
PMCPMC10710304
OpenAlexW4388977536

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.